James Questel
Family Medicine · Gahanna, OHNPI 1689057259
Payments from drug & device makers
Across 138 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- Viiv Healthcare Company$1K
- AbbVie$156
- Napo Pharmaceuticals Inc$126
- Antares Pharma, Inc.$100
- Johnson & Johnson$96
- plus $552 from 11 others
What the payments were for
- Food & beverage$3,152100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 40 | $1,076 |
| Viiv Healthcare Company | 46 | $1,047 |
| AbbVie | 8 | $156 |
| Napo Pharmaceuticals Inc | 4 | $126 |
| Antares Pharma, Inc. | 4 | $100 |
| Johnson & Johnson | 10 | $96 |
| Merck | 3 | $76 |
| Lilly USA, LLC | 4 | $75 |
| Theratechnologies Inc. | 4 | $72 |
| EMD Serono, Inc. | 2 | $62 |
| Novo Nordisk | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Verity Pharmaceuticals Inc. | 1 | $31 |
| Exact Sciences | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,152 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 23 | $49,135 |
| JardianceEmpagliflozin | 33 | $24,889 |
| MounjaroTirzepatide | 17 | $17,427 |
| EliquisApixaban | 14 | $8,179 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,451 |
| Novolog FlexpenInsulin Aspart | 13 | $1,768 |
| Potassium Chloride | 12 | $1,459 |
| Ventolin HfaAlbuterol Sulfate | 12 | $697 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $563 |
| Pregabalin | 22 | $542 |
| Oxycodone Hcl | 16 | $467 |
| Gabapentin | 21 | $382 |
| Metformin Hcl ErMetformin Hcl | 24 | $381 |
| Enalapril Maleate | 12 | $378 |
| Omeprazole | 17 | $254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy | $1,076 | $49,13523 claims |
| Lilly USA, LLCMounjaro | $75 | $17,42717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Gahanna
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.